E-LIB Suche - Ergebnisse für: Sabin, Julia

1

Decisional Conflict Regarding Disease-Modifying Treatment C..:

Sabin, Julia ; Salas, Elisa ; Martín-Martínez, Jesús...
Patient Preference and Adherence. 18 (2024) - p. 1163-1171 , 2024

Link: https://doi.org/10.2147/..

2

Assessing illness-related uncertainty in relapsing-remittin..:

Sabin, Julia ; Salas, Elisa ; Martín-Martínez, Jesús...
Multiple Sclerosis Journal - Experimental, Translational and Clinical. 10 (2024) 2 - p. , 2024

Link: https://doi.org/10.1177/..

3

Illness-related uncertainty and patient experience in relap..:

Sabin, Julia ; Salas, Elisa ; Martín-Martínez, Jesús...
Journal of the Neurological Sciences. 455 (2023) - p. 121863 , 2023

Link: https://doi.org/10.1016/..

4

Baseline Inflammatory Status Reveals Dichotomic Immune Mech..:

Fernández-Velasco, José I. ; Monreal, Enric ; Kuhle, Jens...
Frontiers in Immunology. 13 (2022) - p. , 2022

Link: https://doi.org/10.3389/..

5

Brain Atrophy and Physical and Cognitive Disability in Mult..:

Hospital Universitario de Torrejón, Servicio de Neurología. ; Casanova, Ignacio ; De Silanes, Carlos Lopez...
Basic and Clinical Neuroscience Journal. , 2021

Link: https://doi.org/10.32598..

6

Three-Year Effectiveness of Dimethyl Fumarate in Multiple S..:

Dimethyl Fumarate Study Group ; Pilo de la Fuente, Belen ; Sabín, Julia...
CNS Drugs. 34 (2020) 12 - p. 1275-1286 , 2020

Link: https://doi.org/10.1007/..

7

Tolerability and safety of dimethyl fumarate in relapsing m..:

DMF Study Group ; Sabin, Julia ; Urtiaga, Sarai...
Journal of Neurology. 267 (2020) 8 - p. 2362-2371 , 2020

Link: https://doi.org/10.1007/..

8

Real-World Retrospective Analysis of Alemtuzumab Outcomes i..:

Costa-Frossard França, Lucienne ; Meca Lallana, Virginia ; Labiano-Fontcuberta, Andrés...
CNS Drugs. 38 (2024) 3 - p. 231-238 , 2024

Link: https://doi.org/10.1007/..

9

The Need for the Closer Monitoring of Novel Drugs in MS: A ..:

Sancho-López, Arantxa ; Ruiz-Antorán, Belén ; Hernangómez, Teresa...
Journal of Clinical Medicine. 12 (2023) 20 - p. 6471 , 2023

Link: https://doi.org/10.3390/..

10

Early predictive risk factors for dimethyl fumarate-associa..:

Sainz de la Maza, Susana ; Sabin Muñoz, Julia ; Pilo de la Fuente, Belén...
Multiple Sclerosis and Related Disorders. 59 (2022) - p. 103669 , 2022

Link: https://doi.org/10.1016/..

11

Risk and outcomes of COVID‐19 in patients with multiple scl..:

Moreno‐Torres, Irene ; Meca Lallana, Virginia ; Costa‐Frossard, Lucienne...
European Journal of Neurology. 28 (2021) 11 - p. 3712-3721 , 2021

Link: https://doi.org/10.1111/..

12

Baseline Inflammatory Status Reveals Dichotomic Immune Mech..:

Fernández-Velasco, José I ; Monreal, Enric ; Kuhle, Jens...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977599/. , 2022

Link: http://www.ncbi.nlm.nih...

13

Baseline Inflammatory Status Reveals Dichotomic Immune Mech..:

Fernández Velasco, José I ; Monreal, Enric ; Kuhle, Jens...
Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2022.842354. , 2022

Link: http://hdl.handle.net/24..

14

Three‑Year Effectiveness of Dimethyl Fumarate in Multiple S..:

Pilo De La Fuente, Belén ; Sabín, Julia ; Galán, Victoria...
https://link.springer.com/article/10.1007/s40263-020-00775-9. , 2020

Link: https://hdl.handle.net/1..

15

Response to Fingolimod in Multiple Sclerosis Patients Is As..:

Sánchez-Sanz, Alicia ; Muñoz-Viana, Rafael ; Sabín-Muñoz, Julia...
International Journal of Molecular Sciences. 25 (2024) 3 - p. 1372 , 2024

Link: https://doi.org/10.3390/..